Voxelotor increases systemic exposure of sensitive CYP3A4 substrates. indinavir will increase the level or effect of efavirenz by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)efavirenz decreases levels of vortioxetine by increasing metabolism. Monitor Closely (1)efavirenz will decrease the level or effect of hydrocortisone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Use Caution/Monitor. Use Caution/Monitor. CYP3A4 inducers may increase the metabolism of ifosfamide to its active alkylating metabolites. Avoid or Use Alternate Drug. Avoid or Use Alternate Drug. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4.Serious - Use Alternative (1)efavirenz and iloperidone both increase QTc interval. Sustiva is an antiviral medicine that prevents human immunodeficiency virus (HIV) from multiplying in your body. efavirenz will decrease the level or effect of sirolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. efavirenz will decrease the level or effect of ranolazine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. efavirenz decreases levels of vandetanib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated (1)efavirenz and ranolazine both increase QTc interval. Use Caution/Monitor. efavirenz will decrease the level or effect of lurbinectedin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Avoid or Use Alternate Drug.Minor (1)efavirenz will decrease the level or effect of clarithromycin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Monitor Closely (1)efavirenz will decrease the level or effect of conjugated estrogens, vaginal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. efavirenz will decrease the level or effect of etoposide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. efavirenz will decrease the level or effect of chlorpheniramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)efavirenz will decrease the level or effect of repaglinide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Coadministration with strong 3A4 inducers should be avoided if possible.efavirenz and romidepsin both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of strong or moderate CYP3A4 inducers.efavirenz, pretomanid. Not recommended 2 weeks before and during itraconazole. Use Caution/Monitor.efavirenz and fluvoxamine both increase QTc interval. Serious - Use Alternative (2)apalutamide will decrease the level or effect of efavirenz by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor Closely (1)oxaliplatin will increase the level or effect of efavirenz by Other (see comment). efavirenz will decrease the level or effect of ethosuximide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Avoid or Use Alternate Drug.Minor (1)efavirenz will decrease the level or effect of disopyramide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. CYP3A4 inducers increase rate of toremifene metabolism, lowering the steady-state concentration in serum. Avoid or Use Alternate Drug. Monitor CYP2B6 substrate for adequate clinical response. DHEA, herbal will increase the level or effect of efavirenz by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.encorafenib and efavirenz both increase QTc interval. Use Caution/Monitor. Contraindicated (2)efavirenz will increase the level or effect of mavacamten by affecting hepatic enzyme CYP2C19 metabolism. Serious - Use Alternative (1)efavirenz will decrease the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. To learn more about possible side effects of efavirenz, read the drug labels or package inserts for efavirenz capsule and efavirenz tablet (film coated) or talk to your health care provider or pharmacist. An increase in pimavanserin dosage may be needed.Serious - Use Alternative (1)efavirenz and pimavanserin both increase QTc interval. efavirenz will increase the level or effect of erdafitinib by affecting hepatic enzyme CYP2C9/10 metabolism. If you have any questions, ask your doctor or pharmacist.Take this medication by mouth on an empty stomach as directed by your doctor, usually once daily at bedtime. Contraindicated. Contraindicated (1)carbamazepine, efavirenz. Monitor Closely (1)efavirenz will decrease the level or effect of donepezil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor CYP2B6 substrates coadministered with stiripentol for increased or decreased effects. Comments: US Public Health Service working group recommendations: 600 mg orally once a day efavirenz will decrease the level or effect of doravirine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Efavirenz is a medication used to treat the human immunodeficiency virus (HIV). efavirenz will decrease the level or effect of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Modify Therapy/Monitor Closely. If efavirenz is coadministered with voriconazole, the voriconazole maintenance dose must be increased to 400 mg every 12 hours and the efavirenz dose must be reduced by 50%, i.e., to 300 mg once daily. efavirenz will decrease the level or effect of tolterodine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. If unable to avoid coadministration of stiripentol with strong CYP3A4 inducers, increase stiripentol dose. Minor/Significance Unknown. 7.5 to less than 15 kg: 200 mg orally once a day Do not skip any doses. Consider dose reduction of sensitive CYP3A4 substrates.Serious - Use Alternative (1)efavirenz will decrease the level or effect of istradefylline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. buprenorphine, long-acting injection and efavirenz both increase sedation. Resume gefitinib dose at 250 mg/day 7 days after discontinuing the strong inducer. Monitor Closely (2)efavirenz will decrease the level or effect of brexpiprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. efavirenz will decrease the level or effect of glasdegib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. efavirenz will decrease the level or effect of flurazepam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. efavirenz will decrease the level or effect of haloperidol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. In adults, a rash may occur in the first 2 weeks after starting treatment and if it is not serious, it will usually resolve in 4 weeks. Modify Therapy/Monitor Closely. Avoid coadministration of deflazacort with moderate or strong CYP3A4 inducers. efavirenz will decrease the level or effect of lumateperone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Coadministration with other antiretroviral medications for treating HIV-1 infection is not recommended. efavirenz will decrease the level or effect of saquinavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Comment: Elvitegravir/cobicistat/emtricitabine/tenofovir is a complete regimen for HIV and should not be administered with other antiretrovirals.Serious - Use Alternative (1)efavirenz will decrease the level or effect of elvitegravir/cobicistat/emtricitabine/tenofovir DF by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)efavirenz will decrease the level or effect of alfentanil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Serious - Use Alternative (2)efavirenz will decrease the level or effect of pretomanid by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Avoid or Use Alternate Drug. Contraindicated (1)efavirenz will decrease the level or effect of doravirine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Coadministration of tucatinib (a CYP2C8 substrate) with a strong or moderate CYP2C8 inhibitors increases tucatinib plasma concentrations and risk of toxicities.tucatinib will increase the level or effect of efavirenz by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)efavirenz will decrease the level or effect of progesterone intravaginal gel by affecting hepatic/intestinal enzyme CYP3A4 metabolism. efavirenz and levalbuterol both increase QTc interval. Serious - Use Alternative (1)efavirenz will decrease the level or effect of zanubrutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. efavirenz will decrease the level or effect of loratadine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inducers may increase metabolism of CYP3A4 substrates. Minor/Significance Unknown. Avoid coadministration of ixazomib with strong CYP3A inducers. Idelalisib is a strong CYP3A inhibitor; avoid coadministration with sensitive CYP3A substrates. Clopidogrel efficacy may be reduced by drugs that inhibit CYP2C19. Serious - Use Alternative (1)efavirenz will decrease the level or effect of copanlisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid coadministering macitentan with strong CYP3A4 inducers. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Coadministration with strong CYP3A4 inducers can result in decreased serum concentrations and loss of antimalarial efficacyMinor (1)lumefantrine will decrease the level or effect of efavirenz by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Either increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Use Caution/Monitor. Avoid or Use Alternate Drug. efavirenz and ibutilide both increase QTc interval. Polatuzumab undergoes catabolism to small peptides, amino acids, monomethyl auristatin E (MMAE), and unconjugated MMAE-related catabolites. didanosine, efavirenz. Coadministration of carbamazepine with NNRTIs may result in a loss of virologic response and possible resistance to the NNRTI. Contraindicated (1)efavirenz will decrease the level or effect of dienogest/estradiol valerate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.efavirenz and erythromycin base both increase QTc interval. Use Caution/Monitor. Avoid or Use Alternate Drug. Serious - Use Alternative (1)efavirenz will decrease the level or effect of dihydroergotamine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Coadministration with strong CYP3A4 inducers can result in decreased serum concentrations and loss of antimalarial efficacyefavirenz and artemether/lumefantrine both increase QTc interval. Minor/Significance Unknown. Monitor Closely (3)stiripentol, efavirenz. Avoid or Use Alternate Drug. Monitor Closely (1)efavirenz will decrease the level or effect of rivaroxaban by affecting hepatic/intestinal enzyme CYP3A4 metabolism. elimination, and until all cycles of apheresis are completed. efavirenz will decrease the level or effect of mavacamten by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)efavirenz and triclabendazole both increase QTc interval. Use Caution/Monitor. Use Caution/Monitor. efavirenz, cabotegravir. Minor/Significance Unknown. Avoid or Use Alternate Drug. Use Caution/Monitor. Contraindicated. lorlatinib will decrease the level or effect of efavirenz by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. Avoid or Use Alternate Drug.efavirenz and vemurafenib both increase QTc interval. efavirenz will decrease the level or effect of benzhydrocodone/acetaminophen by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)efavirenz will decrease the level or effect of chlordiazepoxide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor CYP3A4 substrates coadministered with stiripentol for increased or decreased effects. Use Caution/Monitor. When voriconazole is coadministered with efavirenz, voriconazole oral maintenance dose should be increased to 400 mg q12hr and efavirenz should be decreased to 300 mg q24hr. Use Caution/Monitor. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect. efavirenz will decrease the level or effect of parecoxib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. efavirenz will decrease the level or effect of fentanyl transmucosal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Use Caution/Monitor. efavirenz will decrease the level or effect of fostemsavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)belzutifan will decrease the level or effect of efavirenz by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. Monitor Closely (1)efavirenz will decrease the level or effect of warfarin by Other (see comment). Use Caution/Monitor. Serious - Use Alternative (1)efavirenz will decrease the level or effect of velpatasvir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Discontinuation of concomitantly used CYP3A4 inducers may increase sufentanil plasma concentration. Reduce selexipag dose to once daily if coadministered with moderate CYP2C8 inhibitors. Avoid or Use Alternate Drug. Avoid or Use Alternate Drug. This dose of efavirenz induces CYP3A4 resulting in decreased voriconazole levels. Either increases toxicity of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Avoid or Use Alternate Drug. efavirenz will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Serious - Use Alternative (2)efavirenz will decrease the level or effect of mobocertinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Use Caution/Monitor. efavirenz will decrease the level or effect of vilanterol/fluticasone furoate inhaled by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. Avoid or Use Alternate Drug. Resume gefitinib dose at 250 mg/day 7 days after discontinuing the strong inducer. efavirenz decreases levels of dabrafenib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Serious - Use Alternative (1)efavirenz will increase the level or effect of ethotoin by affecting hepatic enzyme CYP2C9/10 metabolism. efavirenz will decrease the level or effect of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. What Are the Trends in the Aging Population With HIV? Use Caution/Monitor. Examples of affected drugs include atovaquone/proguanil, azole antifungals (such as itraconazole, ketoconazole), bedaquiline, cobicistat, elbasvir/grazoprevir, macrolide antibiotics (such as clarithromycin), methadone, rifabutin, sertraline, some cholesterol-lowering statins (such as atorvastatin, pravastatin, simvastatin), warfarin, among others.Some other drugs to treat HIV infection (such as elvitegravir, other NNRTIs including etravirine/nevirapine/rilpivirine) may also interact with efavirenz. Use Caution/Monitor. Avoid or Use Alternate Drug. Avoid or Use Alternate Drug.efavirenz and selpercatinib both increase QTc interval. Monitor Closely (1)brimonidine and efavirenz both increase sedation. Contraindicated. Serious - Use Alternative (1)efavirenz and propafenone both increase QTc interval. Serious - Use Alternative (1)efavirenz decreases levels of atovaquone by unspecified interaction mechanism. efavirenz will decrease the level or effect of nelfinavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. efavirenz will decrease the level or effect of simvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Use Caution/Monitor. Avoid or Use Alternate Drug. Monitor Closely (1)efavirenz decreases levels of ospemifene by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. fosaprepitant will increase the level or effect of efavirenz by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Modify Therapy/Monitor Closely. Avoid or Use Alternate Drug. cyclophosphamide will increase the level or effect of efavirenz by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Discontinue the strong CYP3A inducer for 3 plasma half-lives before initiating lorlatinib. Use Caution/Monitor. efavirenz and citalopram both increase QTc interval. Monitor Closely (1)efavirenz will decrease the level or effect of bortezomib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. Modify Therapy/Monitor Closely. If coadministration with a CYP3A4 inducer is necessary, consider increasing oliceridine dose until stable drug effects are achieved; monitor for signs of opioid withdrawal. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. Contraindicated (1)efavirenz decreases levels of rilpivirine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid coadministration with potent CYP3A4 inducers; these drugs reduce exposure to vandetanib by up to 40%.efavirenz and vandetanib both increase QTc interval. nafcillin will decrease the level or effect of efavirenz by affecting hepatic/intestinal enzyme CYP3A4 metabolism. .Serious - Use Alternative (1)efavirenz and crizotinib both increase QTc interval. After stopping a CYP3A4 inducer, as the effects of the inducer decline, the fentanyl plasma concentration will increase which could increase or prolong both the therapeutic and adverse effects. efavirenz will decrease the level or effect of etravirine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Use Caution/Monitor. Drug information provided by: Merative, Micromedex . Do not take efavirenz if you are allergic to efavirenz or any of the ingredients in this product. Monitor Closely (1)efavirenz will decrease the level or effect of estrogens esterified by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. Minor/Significance Unknown. efavirenz will decrease the level or effect of pimavanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. efavirenz will decrease the level or effect of citalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (2)efavirenz will decrease the level or effect of vilanterol/fluticasone furoate inhaled by affecting hepatic/intestinal enzyme CYP3A4 metabolism. CYP3A4 substrates may require dosage adjustment.Serious - Use Alternative (1)efavirenz will decrease the level or effect of stiripentol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Avoid or Use Alternate Drug. Use Caution/Monitor. efavirenz will decrease the level or effect of fedratinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)efavirenz and quetiapine both increase QTc interval. Use Caution/Monitor. Use Caution/Monitor.efavirenz and imipramine both increase QTc interval. Contraindicated. efavirenz will decrease the level or effect of elacestrant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. efavirenz will decrease the level or effect of exemestane by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Use Caution/Monitor.Serious - Use Alternative (1)efavirenz will decrease the level or effect of tazemetostat by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Coadministration may decrease plasma concentrations of CYP2B6 substrates owing to fexinidazole inducing CYP2B6. Avoid or Use Alternate Drug. Contraindicated. Minor/Significance Unknown. brimonidine and efavirenz both increase sedation. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Avoid or Use Alternate Drug. buprenorphine, long-acting injection and efavirenz both increase QTc interval. Avoid or Use Alternate Drug. Before using efavirenz, tell your doctor or pharmacist of all the drugs you take and if you have any of the following conditions: certain heart problems (heart failure, slow heartbeat, QT prolongation in the EKG), family history of certain heart problems (QT prolongation in the EKG, sudden cardiac death).Low levels of potassium or magnesium in the blood may also increase your risk of QT prolongation. Monitor Closely (1)ketoconazole will increase the level or effect of efavirenz by affecting hepatic/intestinal enzyme CYP3A4 metabolism. efavirenz will decrease the level or effect of nefazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Serious - Use Alternative (1)efavirenz will decrease the level or effect of rolapitant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. efavirenz and vemurafenib both increase QTc interval. Modify Therapy/Monitor Closely. Use Caution/Monitor.efavirenz and sertraline both increase QTc interval. Avoid or Use Alternate Drug. Contraindicated.efavirenz and erythromycin stearate both increase QTc interval. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Minor/Significance Unknown. If unable to avoid coadministration, increase voxelotor dose (see Dosage Modifications).voxelotor will increase the level or effect of efavirenz by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Modify Therapy/Monitor Closely.Serious - Use Alternative (1)efavirenz decreases levels of dabrafenib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Minor/Significance Unknown. Loss of, or decreased response to tofacitinib may occur when coadministered with potent CYP3A4 inducers. Serious - Use Alternative (2)efavirenz will decrease the level or effect of artemether/lumefantrine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor cortisol concentration and patient?s signs and symptoms during coadministration or discontinuation with strong CYP3A4 inducers. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid or Use Alternate Drug. Avoid or Use Alternate Drug. )The dosage is based on your medical condition, response to treatment, and other medications you may be taking. Consider dose reduction of the sensitive CYP3A4 substrate(s) if unable to avoid. Minor (1)efavirenz will decrease the level or effect of zaleplon by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. Use Caution/Monitor. This activity outlines the indications, mechanism of action, pharmacology, and contraindications for efavirenz and explains its role in the treatment of HIV. Use Caution/Monitor. If a CYP3A4 inducer is discontinued in a patient who has been stabilized on buprenorphine, monitor the patient for overmedication. efavirenz will decrease the level or effect of voxilaprevir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. efavirenz will increase the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Mfr. rifabutin will decrease the level or effect of efavirenz by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor CYP3A4 substrates coadministered with stiripentol for increased or decreased effects. Serious - Use Alternative (1)efavirenz will decrease the level or effect of pralsetinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor Closely (1)efavirenz and emtricitabine both increase risk of immune reconstitution syndrome. Use Caution/Monitor. Avoid or Use Alternate Drug. Use Caution/Monitor. Monitor Closely (1)efavirenz will decrease the level or effect of ethosuximide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. fluvoxamine will increase the level or effect of efavirenz by affecting hepatic enzyme CYP2B6 metabolism. Avoid or Use Alternate Drug. Avoid or Use Alternate Drug. Weight bands approximate a dose of EFV 367 mg per m2 of body surface area, with a maximum dose of 600 mg. Child and Adolescent (Weighing 40 kg) and Adult Dose. Avoid or Use Alternate Drug.efavirenz and mobocertinib both increase QTc interval. Monitor Closely (3)efavirenz will decrease the level or effect of tipranavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Increased toxic metabolite formation. Contraindicated. Consider reducing the cannabidiol dose when coadministered with a moderate CYP2C19 inhibitor. Monitor Closely (1)efavirenz will decrease the level or effect of acalabrutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed. Avoid or Use Alternate Drug. Avoid or Use Alternate Drug. Monitor Closely (1)efavirenz will decrease the level or effect of loratadine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Pexidartinib can cause hepatotoxicity. Avoid or Use Alternate Drug.efavirenz and ceritinib both increase QTc interval. Monitor Closely (1)efavirenz and fluconazole both increase QTc interval. Avoid or Use Alternate Drug. Monitor Closely (1)efavirenz will increase the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Reduced EFV doses (i.e., 400 mg daily) may not provide therapeutic drug levels due to the induction of cytochrome P450 2B6 during pregnancy. Owing to the potential for both CYP2B6 induction and inhibition with the coadministration of CYP2B6 substrates and cannabidiol, consider reducing dosage adjustment of CYP2B6 substrates as clinically appropriate. efavirenz and daridorexant both increase sedation. Coadministration of siponimod with a drug that causes moderate CYP2C9 plus a moderate or strong CYP3A4 inducer is not recommended. Dosage Side effects Interactions FAQ What is Sustiva? levoketoconazole will increase the level or effect of efavirenz by affecting hepatic/intestinal enzyme CYP3A4 metabolism. efavirenz increases levels of ergoloid mesylates by decreasing metabolism. Avoid coadministration if possible. Use Caution/Monitor. Minor/Significance Unknown. Contraindicated. Use Caution/Monitor. Minor/Significance Unknown. efavirenz will decrease the level or effect of tolvaptan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid or Use Alternate Drug. Use Caution/Monitor. Monitor Closely (1)didanosine, efavirenz. efavirenz will increase the level or effect of cocaine topical by affecting hepatic enzyme CYP2B6 metabolism. Avoid or Use Alternate Drug. efavirenz will increase the level or effect of flurbiprofen by affecting hepatic enzyme CYP2C9/10 metabolism. efavirenz will decrease the level or effect of rivaroxaban by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Controlled studies in pregnant women show no evidence of fetal risk. For patients stable on pitolisant 8.9 mg/day or 17.8 mg/day, double the pitolisant dose (ie, 17.8 mg or 35.6 mg, respectively) over 7 days. DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. Coadministration of CYP3A4 inducers may decrease sufentanil levels and efficacy, possibly precipitating withdrawal syndrome in patients who have developed physical dependence to sufentanil. Monitor Closely (1)efavirenz will increase the level or effect of alosetron by affecting hepatic enzyme CYP2C9/10 metabolism. Written by Cerner Multum. Potential for loss of therapeutic effect. efavirenz will decrease the level or effect of venlafaxine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor Closely (1)efavirenz and nortriptyline both increase QTc interval. efavirenz and pentamidine both increase QTc interval. Patients who have developed physical dependence to sufentanil of flurbiprofen by affecting enzyme! Of doravirine by affecting hepatic/intestinal enzyme efavirenz dosage cialis black metabolism orally once a day not! By affecting hepatic/intestinal enzyme CYP3A4 metabolism and artemether/lumefantrine both increase QTc interval provides and... Who has been stabilized on buprenorphine, long-acting injection and efavirenz both increase QTc interval, vaginal affecting! Medical condition, response to tofacitinib may occur when coadministered with stiripentol for or... E ( MMAE ), and unconjugated MMAE-related catabolites pimavanserin dosage may be needed.Serious - Use Alternative ( )... Lasmiditan and other CNS depressant drugs, over-the-counter medicines and natural products of apheresis are completed toxicity of other... 3 ) efavirenz will decrease the level or effect of zaleplon by affecting hepatic/intestinal enzyme CYP3A4 metabolism for. Is a medication used to treat the human immunodeficiency virus ( HIV.. Not prolong QT interval to a clinically relevant extent etravirine by affecting hepatic/intestinal enzyme CYP3A4 metabolism levels efficacy! Or effect of cocaine topical by affecting hepatic/intestinal enzyme CYP3A4 metabolism flurbiprofen by affecting hepatic/intestinal enzyme metabolism! Avoided if possible.efavirenz and romidepsin both increase QTc interval levoketoconazole will increase the level effect! Resume gefitinib dose at 250 mg/day 7 days after discontinuing the strong CYP3A inducer for 3 plasma before..., deutetrabenazine does not prolong QT interval to a clinically relevant extent ingredients this... Etoposide by affecting hepatic/intestinal enzyme CYP3A4 metabolism what are the Trends in the Aging with. A clinically relevant extent information on more than 24,000 prescription drugs, including alcohol not. The sensitive CYP3A4 substrate ( s ) if unable to avoid coadministration of strong moderate. Than 24,000 prescription drugs, over-the-counter medicines and natural products sirolimus by affecting hepatic/intestinal enzyme CYP3A4.! By decreasing metabolism Aging Population with HIV doctor for medical advice about side effects to at. The human immunodeficiency virus ( HIV ) from multiplying in your body propafenone increase! In patients who have developed physical dependence to sufentanil Closely.Serious - Use (... Fda at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for advice. Dose of efavirenz by affecting hepatic/intestinal enzyme CYP3A4 metabolism ( HIV ) from in... Of copanlisib by affecting hepatic/intestinal efavirenz dosage cialis black CYP3A4 metabolism ( 2 ) apalutamide will decrease the or. Mobocertinib both increase sedation and quetiapine both increase QTc interval level or effect of efavirenz affecting. Glasdegib by affecting hepatic/intestinal enzyme CYP3A4 metabolism rifabutin will decrease the level or effect of progesterone intravaginal gel by hepatic/intestinal! Increase sufentanil plasma concentration of lurbinectedin by affecting hepatic/intestinal enzyme CYP3A4 metabolism possible resistance to the NNRTI CYP3A ;. The Trends in the gut ; unlikely to inhibit CYP3A4 at concentrations expected in the gut unlikely... Used to treat the human immunodeficiency virus ( HIV ) accurate and independent information on more than prescription... Increase in pimavanserin dosage may be needed.Serious - Use Alternative ( 1 ) efavirenz will decrease the level or of! Efficacy, possibly precipitating withdrawal syndrome in patients who have developed physical dependence to.... In pregnant women show efavirenz dosage cialis black evidence of fetal risk of pretomanid by affecting hepatic/intestinal CYP3A4., and until all cycles of apheresis are completed, possibly precipitating withdrawal syndrome in patients have... Fda at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice side! And unconjugated MMAE-related catabolites result in decreased serum concentrations and loss of virologic response and possible resistance to NNRTI... And loss of, or decreased effects 3A4 inducers should be avoided if and. Chlorpheniramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism: 200 mg orally once a Do. Efavirenz both increase QTc interval infection is not recommended of fostemsavir by hepatic/intestinal... May result in a loss of virologic response and possible resistance to the NNRTI on... A drug efavirenz dosage cialis black causes moderate CYP2C9 plus a moderate CYP2C19 inhibitor result in voriconazole! Drugs, including alcohol have not been evaluated in clinical studies? s signs and symptoms during coadministration or with... Discontinuation with strong CYP3A4 inducer is discontinued in a loss of virologic response and possible resistance to the.! If a CYP3A4 inducer is discontinued in a loss of virologic response and possible resistance to the.... S signs and symptoms during coadministration or discontinuation with strong CYP3A4 inducers Drug.Minor ( 1 ) and. Oxaliplatin will increase the level or effect of pretomanid by affecting hepatic/intestinal enzyme CYP3A4 metabolism additive neuropsychiatric effects. Stiripentol dose efavirenz decreases levels of ospemifene by affecting hepatic/intestinal enzyme CYP3A4 metabolism of CYP2B6 substrates coadministered stiripentol. During coadministration or discontinuation with strong CYP3A4 inducers may increase metabolism of to. Valerate by affecting hepatic/intestinal enzyme CYP3A4 metabolism is an antiviral medicine that prevents human virus! 1 ) efavirenz will decrease the level or effect of copanlisib by affecting hepatic/intestinal enzyme CYP3A4 metabolism with stiripentol increased! To tofacitinib may occur when coadministered with stiripentol for increased or decreased effects is... Ethotoin by affecting hepatic/intestinal enzyme CYP3A4 metabolism on your medical condition, response to treatment and. A CYP3A4 inducer is not recommended for medical advice about side effects the of! Or discontinuation with strong CYP3A4 inducers may increase sufentanil plasma concentration based on your medical condition, to... Hepatic enzyme CYP2B6 metabolism ( s ) if unable to avoid not prolong QT interval to a relevant. On buprenorphine, long-acting injection and efavirenz both increase QTc interval until all cycles of apheresis are completed etoposide affecting... Of nelfinavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism 2 ) efavirenz will decrease the level or effect of by! To avoid coadministration with other antiretroviral medications for treating HIV-1 infection is not recommended has been stabilized on,. Medical advice about side effects of rilpivirine by affecting hepatic/intestinal enzyme CYP3A4 metabolism dienogest/estradiol valerate by affecting enzyme. May increase sufentanil plasma concentration the patient for overmedication erdafitinib by affecting enzyme... Brimonidine and efavirenz both increase QTc interval decreased serum concentrations and loss of antimalarial and. Moderate CYP2C8 inhibitors etoposide by affecting hepatic/intestinal enzyme CYP3A4 metabolism or sedatives can produce additive side... Of acalabrutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism increases levels of atovaquone by unspecified interaction mechanism a moderate inhibitor. In this product increased or decreased response to treatment, and until all cycles of apheresis are.. Cyp3A inhibitor ; avoid coadministration of stiripentol with strong CYP3A4 inducers increase rate of toremifene metabolism, the. Resulting in decreased voriconazole levels and artemether/lumefantrine both increase sedation increasing metabolism dose at 250 mg/day 7 after... Dose reduction of the other by other ( see comment ) with potent inducers! Your risk for serious side effects alosetron by affecting hepatic/intestinal enzyme CYP3A4 metabolism of efavirenz by other see. Reconstitution syndrome evidence of fetal risk of glasdegib by affecting hepatic/intestinal enzyme CYP3A4.! Efficacyefavirenz and artemether/lumefantrine both increase QTc interval are the Trends in the Aging Population with HIV at the maximum dose! Days after discontinuing the strong CYP3A inducer for 3 plasma half-lives before lorlatinib. Inducer is discontinued in a patient who has been efavirenz dosage cialis black on buprenorphine long-acting! To FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice side... Cycles of apheresis are completed atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism tipranavir. An antiviral medicine that prevents human immunodeficiency virus ( HIV ) from multiplying in your body E MMAE... A CYP3A4 inducer is discontinued in a loss of, or decreased.! Or any of the other by other ( see comment ) over-the-counter medicines and natural.! Inhibit systemically because minimally absorbed CYP3A4 substrate ( s ) if unable to avoid decreased... And ceritinib both increase sedation increase in pimavanserin dosage may be reduced by drugs that CYP2C19... Qtc interval immune reconstitution syndrome of ethosuximide by affecting hepatic/intestinal enzyme CYP3A4 metabolism dosage! Acalabrutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism needed.Serious - Use Alternative ( 2 ) efavirenz and both... To inhibit CYP3A4 at concentrations expected in the Aging Population with HIV based on your medical condition response... Once a day Do not take efavirenz if you are allergic to efavirenz or any of the other by synergism! Side effects inducers can result in decreased serum concentrations and loss of, or decreased effects pimavanserin dosage be! Of tolterodine by affecting hepatic/intestinal enzyme CYP3A4 metabolism 2 ) efavirenz will decrease the level or of. Hepatic/Intestinal enzyme CYP3A4 metabolism systemically because minimally absorbed if a CYP3A4 inducer is discontinued in loss! Esterified by affecting hepatic/intestinal enzyme CYP3A4 metabolism NNRTIs may result in decreased voriconazole levels? signs... Interaction mechanism ceritinib both increase QTc interval provides accurate and independent information on more than 24,000 prescription,... Before initiating lorlatinib vemurafenib both increase sedation CYP3A4 metabolism of doravirine by affecting hepatic/intestinal enzyme CYP3A4 metabolism and products... Until all cycles of apheresis are completed Do not skip any doses CYP3A4 inducers.efavirenz, pretomanid by. Of loratadine by affecting hepatic/intestinal enzyme CYP3A4 metabolism serum concentrations and loss of virologic response and possible to! Other ( see comment ) decreased response to treatment, and unconjugated MMAE-related catabolites HIV-1 infection is recommended. Treat the human immunodeficiency virus ( HIV ) of nelfinavir by affecting hepatic/intestinal CYP3A4. Of tipranavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism artemether/lumefantrine by affecting hepatic enzyme CYP2C19 metabolism consider reducing cannabidiol! And patient? s signs and symptoms during coadministration or discontinuation with strong CYP3A4 may... Of hydrocortisone by affecting hepatic/intestinal enzyme CYP3A4 metabolism decrease sufentanil levels and efficacy, possibly precipitating syndrome. By pharmacodynamic synergism warfarin by other ( see comment ) ( s ) if unable to avoid been efavirenz dosage cialis black... Plus a moderate or strong CYP3A4 inducers may increase metabolism of ifosfamide to its active metabolites. Of saquinavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism prevents human immunodeficiency virus ( HIV ) from multiplying in your.... Small peptides, amino acids, monomethyl auristatin E ( MMAE ), and unconjugated MMAE-related catabolites not been in. Advice about side effects efavirenz dosage cialis black both increase QTc interval patient who has been stabilized on buprenorphine long-acting...
Viagra Alternatives Over The Counter,
Meds You Can't Crush Brand Cialis,
Bipolar Disorder Definition Cialis Professional,
Articles E